Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuronetics (STIM) Change in Accured Expenses (2017 - 2025)

Neuronetics (STIM) has disclosed Change in Accured Expenses for 9 consecutive years, with -$3.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses fell 235.98% to -$3.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$4.2 million, a 403.09% decrease, with the full-year FY2024 number at -$2.1 million, up 7.13% from a year prior.
  • Change in Accured Expenses was -$3.0 million for Q3 2025 at Neuronetics, down from -$127000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $3.3 million in Q4 2022 to a low of -$7.7 million in Q1 2023.
  • A 5-year average of -$6000.0 and a median of $310000.0 in 2021 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 648.3% in 2021, then tumbled 1618.12% in 2023.
  • Neuronetics' Change in Accured Expenses stood at $1.3 million in 2021, then skyrocketed by 154.3% to $3.3 million in 2022, then dropped by 23.5% to $2.6 million in 2023, then tumbled by 135.85% to -$917000.0 in 2024, then plummeted by 225.19% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for STIM's Change in Accured Expenses are -$3.0 million (Q3 2025), -$127000.0 (Q2 2025), and -$193000.0 (Q1 2025).